Skip to main content
. 2015 Dec 23;7(17):23212–23226. doi: 10.18632/oncotarget.6745

Figure 2. LINC00668 is a direct target of E2F1.

Figure 2

A. Analysis of LINC00668 expression levels in GC cell lines (SGC-7901, BGC-823 and MGC-803) compared with the normal gastric epithelium cell line (GES-1) by qRT-PCR. B. Description of E2F1 binding sites in the promoter region of LINC00668. The position of ChIP primers F. was indicated by arrows. C. Western blot assays detected the expression of E2F1 after the transfection of the overexpression plasmid and si-RNA. D. The expression of LINC00668 and ANRIL was determined in E2F1 and si-E2F1 systems in BGC-823 and SGC-7901 cells. E. The luciferase assays were performed to detect the promoter activity of LINC00668. Induction of LINC00668 promoter activity by E2F1 in BGC-823 cells. Then, deletion analysis of the promoter activity was performed to determine the role of the E2F1 site in E2F1-mediated regulation of LINC00668. F. Enrichment of E2F1 in the LINC00668 promoter after E2F1 overexpression. E2F1 was immunoprecipitated, and the promoter region containing E2F1-binding sequences were quantified by qRT-PCR. The ChIP primers are detailed in Supplementary Table S3. G. Immunohistochemistry was used to detect the expression of the E2F1 protein in GC and corresponding non-tumor tissues. Bar, 100μm. H. The immunoreactivity of the E2F1 protein in GC tissues showed a statistically significant positive correlation with the relative level of LINC00668 expression. Error bars indicate the means±S.E.M. *P < 0.05, **P < 0.01. n.s., not significant.